The use of canine mesenchymal stem cells for the autologous treatment of osteoarthritis by Srzentić Dražilov, Sanja et al.
Acta Veterinaria Hungarica 66 (3), pp. 376–389 (2018) 
DOI: 10.1556/004.2018.034 
 
0236-6290/$ 20.00 © 2018 Akadémiai Kiadó, Budapest 
THE USE OF CANINE MESENCHYMAL STEM CELLS FOR THE 
AUTOLOGOUS TREATMENT OF OSTEOARTHRITIS 
Sanja SRZENTIĆ DRAŽILOV1, Janko MRKOVAČKI2, Vesna SPASOVSKI1, Amira FAZLAGIĆ3, 
Sonja PAVLOVIĆ1 and Gordana NIKČEVIĆ1* 
1Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic  
Engineering, University of Belgrade, Vojvode Stepe 444a, P.O. Box 23, 11010 Belgrade, 
Serbia; 2Stem Art Ltd., Belgrade, Serbia; 3National Association for the Improvement and 
Development of Regenerative Medicine, Belgrade, Serbia 
(Received 12 December 2017; accepted 25 July 2018) 
Mesenchymal stem cells (MSCs) hold enormous potential for cell-based 
therapy in the treatment of various diseases, particularly those which currently 
cannot be cured and result in poor outcomes or invasive surgery. Here we present 
results of the application of autologous, culture-expanded, adipose tissue (AT)-
derived MSCs for the osteoarthritis (OA) treatment of 10 canine patients. The 
stemness of isolated cells has been confirmed by their ability to differentiate into 
osteo- and chondrocytic lineages. The clinical effect of a single injection of AT-
MSCs into the symptomatic joints was evaluated by a veterinarian for five disabil-
ities characteristic of OA at 30, 60 and 90 days after treatment, which has been 
designated as the initial evaluation period. Functional outcomes for all analysed 
characteristics improved significantly at the end of this evaluation compared with 
the baseline. In addition, for 5 of these 10 patients, an extended follow-up study 
was performed from 1 to 4 years after the initial evaluation period. We detected 
long-lasting positive effects on two out of five analysed characteristics. The re-
sults demonstrate that the use of autologous AT-MSCs is a successful approach to 
canine OA therapy.  
Key words: Canine, osteoarthritis, mesenchymal stem cells, extended fol-
low-up 
Osteoarthritis (OA) is the most common form of joint disease. It is charac-
terised by progressive degeneration of the articular cartilage, synovial inflamma-
tion, insufficient repair response that leads to cartilage loss, joint space narrow-
ing and, finally, joint destruction (Elders, 2000; Guercio et al., 2012; Man and 
Mologhianu, 2014). OA is a major clinical problem in veterinary medicine, par-
ticularly for dogs, since it affects ~20% of these animals (Guercio et al., 2012; 
Evans et al., 2013). Severe OA causes chronic pain, stiffness of the joint, degen-
eration and effusion, leading to significantly reduced joint function, lameness and 
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consequently to deterioration in the patient’s quality of life (Pers and Jorgensen, 
2013).  
Despite the considerable efforts put into the development of effective 
pharmacological or surgical treatments, clinical success with respect to the pre-
vention of cartilage matrix deterioration or cartilage restoration in OA remains 
elusive (Deschner et al., 2003; Verbruggen, 2006). 
Mesenchymal stem cells (MSCs) have emerged as a promising alternative 
approach to treat cartilage disorders, mainly due to their regenerative and im-
munomodulatory properties (Arnhold and Wenisch, 2015; Zhang et al., 2016). 
These cells are ideal candidates for regenerative medicine, since they can be rela-
tively easily harvested from their resident tissues, such as adipose tissue (AT) 
and bone marrow, and expanded in culture over several passages to reach suffi-
cient numbers for clinical use. Also, upon implantation in sites of tissue damage, 
MSCs provide signals which favourably influence the activities of cells in the 
surrounding (Caplan and Dennis, 2006). All these properties make MSCs suita-
ble for use as therapeutic agents in vivo, especially for regenerating damaged tis-
sues in diseases of the locomotor system (Lavoie and Rosu-Myles, 2013). 
The goal of this study was to evaluate the short- and long-term effects of 
the application of autologous MSCs from adipose tissue for the treatment of os-
teoarthritis in dogs. 
 
Materials and methods 
Animals 
Ten canine patients with different joints showing the signs of osteoarthritis 
were included in the autologous AT-MSCs treatment. The degree of osteoarthri-
tis was established based on the physical examination as follows: I – Reluctance 
of the animal to perform certain tasks or manoeuvres without obvious signs of 
stiffness or lameness; II – Lameness and stiffness occur after periods of sustained 
activity or after brief overexertion, and the clinical signs often disappear after 
several days; III – Most pronounced stiffness after periods of rest, and the ani-
mals appear to ‘warm out’ of their lameness or stiffness. Cold and damp weather 
often increases the severity of clinical signs; IV – Stiffness and lameness are fair-
ly constant features, although the severity of signs may still be influenced by en-
vironmental factors. Affected animals may show signs of increased irritability 
and reclusiveness, and may snap or bite when approached or touched (Pedersen 
et al., 2000).  
All patients completed the initial evaluation period of this study (up to 90 
days after treatment). Also, for five of these patients an extended follow-up was 
performed (1–4 years after the initial evaluation period), marked as ‘1 year +’ pe-
riod. All patients’ characteristics and diagnoses are presented in Table 1. One pa-
tient (no. 5) had additional diagnoses besides OA. Due to the fractures, this pa-
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tient developed irregular ankylosis of the carpometacarpal and intercarpal joints 
that led to the development of OA of the radiocarpal joint. Two patients (no. 4 
and 11) died during the extended follow-up study due to diseases unrelated to 
MSCs treatment. 
All dogs included in this study were client-owned animals. Adipose tissue 
collection and AT-MSCs therapy were approved and certified by the dog owners 
with a signed informed consent. AT collection was performed using anaesthetics, 
and AT-MSCs therapy was performed using sedatives, which excluded the pain, 
suffering, fear and stress of the animals, in accordance with the standards of good 
veterinary practice, the guidelines of good laboratory practice, Directive 2010/ 
63/EU of the European Parliament and of the Council of 22 September 2009, as 
well as the European Convention for the protection of vertebrates intended for 
experimental and other scientific purposes (ETS 170). 
Isolation and culture of AT-MSCs for OA treatment 
Subcutaneous adipose tissue from the paralumbar region (on the border-
line of the middle and the caudal lateral abdominal region) of each patient was 
collected by routine veterinary surgery procedures. Adipose tissue MSCs were 
isolated by collagenase digestion method as described previously (Zuk et al., 2002; 
Yu et al., 2011) and subsequently 6 × 104 cells per cm2 were seeded to the tissue 
culture flasks. Throughout the complete cultivation period, cells were grown in 
the medium containing 10% of autologous serum in an incubator at 37 °C and 
5% CO2. After seeding, MSCs were allowed to adhere to the plastic surface of 
tissue culture dishes for seven days, at which point the medium was changed in 
order to remove unattached cells and debris. After this step, the medium was re-
newed every three days and cultivation continued until the number of cells 
reached the level of > 3 × 107. This number of cells resuspended in PBS was 
used for the injection in the symptomatic joint, or in the case of bilateral OA it 
was split in half. 
Differentiation of AT-MSCs 
Cells derived from adipose tissue and expanded in the growth medium 
with autologous serum were used for differentiation studies. For the control of 
stemness, the MSCs were cultured in appropriate differentiation media in order 
to obtain osteogenic and chondrogenic lineages. In these experiments the differ-
entiation media were supplemented with 10% fetal calf serum. All studies were 
carried out with the same number of controls. 
Osteogenic differentiation 
Differentiation of isolated and cultured AT-MSCs toward osteogenic line-
age and detection of extracellular calcium deposits by Alizarin Red S staining was 
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performed as described here: http://www.promocell.com/fileadmin/knowledgebase/ 
pdf-xls/Osteogenic_Differentiation_and_Analysis_of_MSC.pdf. Accessed 15 No-
vember 2017, except for the osteogenic medium which was composed according 
to Mesimaki et al. (2009). 
Chondrogenic differentiation 
Differentiation toward chondrogenic lineage and Alcian blue staining of 
glycosaminoglycans was performed as described here: http://www.promocell.com/ 
fileadmin/knowledgebase/pdf-xls/Chondrogenic_Differentiation_and_Analysis_ 
of_MSC.pdf. Accessed 15 November 2017, except for the chondrogenic medium 
which was composed according to Vidal et al. (2008). 
Clinical evaluation 
Veterinary evaluation consisted of physical examination and assessment 
for lameness, pain on manipulation, range of motion of the joint and functional 
disability using a numeric rating scale at baseline and specified intervals. For all 
10 dogs evaluation was performed up to 90 days after treatment (the initial eval-
uation period). Additionally, for 5 dogs evaluation was performed up to 4 years 
after the initial evaluation period (the extended follow-up). The clinical outcome 
measures were based on veterinary assessment using questionnaires and the nu-
meric rating scale, which is presented in Table 2. Pain on manipulation was as-
sessed by the combination of scores for palpation and joint manipulation, in 
which the motion of the joint was below its physiological limits of mobility. 
Range of motion of the joint assessment involved manipulation of the joint up to 
its physiological limits of mobility. In addition, for all dogs diagnosed with hip 
OA, during physical examination of the pain on manipulation, adduction, abduc-
tion and circumduction manipulations were performed (besides flexion and ex-
tension). None of the animals displayed pain during these three additional ma-
nipulations, and therefore they are not listed in Table 2. 
Statistical analysis 
Results were analysed using Wilcoxon signed-rank test. Two-sided P val-
ue was used and differences were considered to be significant when P < 0.05. 
The effect size (r) was calculated and it was considered to be: r = 0.1 – small ef-
fect; r = 0.3 – medium effect; r = 0.5 – large effect (Pallant, 2007). Data were an-
alysed using the SPSS for Windows 20.0 software (IBM Corp., Armonk, NY, 
USA). 
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Results 
Differentiation of AT-MSCs 
Adipose tissue-MSCs were successfully isolated from all samples, show-
ing the characteristic property to adhere to culture dishes and displaying fibro-
blast-like morphology. The stemness of isolated and cultured cells was con-
firmed by their ability to differentiate into osteo- and chondrocytic lineages. Cul-
tivation of AT-MSCs in osteogenic medium led to the production of calcium de-
posits within their extracellular matrix, characteristic for osteoblasts, that was ev-
idenced with Alizarin red S staining (Figs 1a and 1b). When AT-MSCs were 
grown in three-dimensional spheroid culture, only cells cultured in chondrogenic 
medium showed the presence of glycosaminoglycans, components of cartilage 
extracellular matrix, demonstrated by Alcian blue staining (Figs 2a and 2b). 
 
Fig. 1. Osteogenesis-induced differentiation of canine adipose tissue-derived mesenchymal stem 
cells (AT-MSCs). (a) AT-MSCs under osteogenic conditions for three weeks produced  
calcium-containing mineralised matrix as demonstrated by Alizarin red S dye incorporation;  
(b) no specific staining was observed in cultures maintained under control conditions.  
Magnification: × 10, scale bar = 100 µm 
 
Fig. 2. Chondrogenesis-induced differentiation of canine AT-MSCs. (a) Specific Alcian blue  
staining of glycosaminoglycans produced by AT-MSCs in three-dimensional spheroid cultured  
under chondrogenic conditions for three weeks; (b) no specific staining was observed in cultures 
maintained under control conditions. Magnification: × 10, scale bar = 100 µm 
a b
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Clinical evaluation  
All dogs completed the 90-day study, which was designated as the initial 
evaluation period. Comparison of scores of assessment at baseline and 90 days 
after AT-MSCs injection showed statistically significant improvement for all as-
sessed impairments with a large effect size: lameness at walk (P = 0.010, Z =  
–2.588, r = 0.579) (Fig. 3a), lameness at trot (P = 0.004, Z = –2.873, r = 0.643) 
(Fig. 3b), pain on manipulation (P = 0.003, Z = –3.00, r = 0.671) (Fig. 3c), range 
of motion of the joint (P = 0.007, Z = –2.701 , r = 0.604) (Fig. 3d), and function-
al disability (P = 0.011, Z = –2.546, r = 0.570) (Fig. 3e). Mean values of scores at 
these two evaluation points (baseline and 90 days post treatment) had dropped 
for all analysed characteristics (Fig. 3), with the biggest change detected for 
lameness at trot (from 4.40 to 1.20; Fig. 3b). 
Regarding the extended follow-up study (the ‘1 year +’ period), five out of 
ten patients were available for examination. When the results of evaluation were 
compared between baseline and the ‘1 year +’ period, statistically significant im-
provement with a large effect size was detected for lameness at trot (P = 0.046, 
Z = –2.000, r = 0.632) (Fig. 4b), and for the range of motion of the joint (P = 
0.041, Z = –2.041, r = 0.645) (Fig. 4d). Statistically significant improvement was 
not detected for lameness at walk (P = 0.066, Z = –1.841, r = 0.582) (Fig. 4a), 
pain on manipulation (P = 0.180, Z = –1.342, r = 0.424), (Fig. 4c), and functional 
disability (P = 0.104, Z = –1.625, r = 0.514) (Fig. 4e). Regarding the mean values 
of scores at these assessment points (baseline and ‘1 year +’ post treatment), the 
same trend was detected as after the initial evaluation period, i.e. values had 
dropped for all analysed characteristics (Fig. 4). Again, the biggest change was 
observed for lameness at trot that had changed from 4.40 to 1.20 (Fig. 4b). It is 
worth mentioning that between the end of the initial evaluation period and the ‘1 
year +’ period only mild changes were observed in mean values of scores for all 
analysed characteristics. 
 
Discussion 
Articular cartilage lesions, as in OA, remain a major unsolved clinical 
problem in both veterinary and human medicine (Kong et al., 2017). One of the 
main characteristics of this pathology is the poor repair capacity of the affected 
tissue. Despite enormous research efforts in this field, no effective OA-
modifying drug is currently available, as well as no conservative or operative 
treatments that would restore the articular cartilage integrity (de Bakker et al., 
2013; Pers and Jorgensen, 2013; Kong et al., 2017). These shortcomings, accom-
panied by the increased spontaneous occurrence of articular cartilage defects in 
multiple joints in both animals (dogs in particular) and humans, have led to the 
increased interest in MSCs as a novel treatment option for this disease (de Bak-
ker et al., 2013; Kong et al., 2017). In several preclinical studies with animal 
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models of OA successful cartilage regeneration was reported after injection of 
MSCs into the damaged joint. For example, in the murine model of collagenase-
induced OA a single MSCs injection into the knee joint produced a significant 
decrease in synovitis score and cartilage damage (ter Huurne et al., 2012). Other 
studies using larger animal models of OA, such as rat (Horie et al., 2012), guinea 
pig (Sato et al., 2012), rabbit (Toghraie et al., 2012; Desando et al., 2013), goat 
(Murphy et al., 2003) and donkey (Mokbel et al., 2011) revealed similar results 
by applying MSCs. 
Regarding dogs, the efficacy of MSCs therapy has been mainly reported 
for spontaneously occurring OA (de Bakker et al., 2013). Variation in the sample 
size and the duration of follow-up between studies is widely present. Improve-
ment in outcome measures of the hip joints was reported following single intraar-
ticular injection of autologous AT-MSCs for 18 dogs with chronic OA after a pe-
riod of three (Black et al., 2007) and six months (Cuervo et al., 2014) and for 
eight dogs after a period of six months (Vilar et al., 2013). Functional improve-
ments in disabilities caused by chronic OA of the elbow joints was described for 
14 dogs after a period of six months (Black et al., 2008) and for four dogs one 
month after treatment with autologous MSCs in either platelet-rich plasma or hy-
aluronic acid (HA) (Guercio et al., 2012). Using a follow-up period of one year, 
significant improvement in their disability was reported for the majority of 30 
dogs with osteoarthritic elbow joints treated with allogeneic AT-MSCs in HA 
(Kriston-Pal et al., 2017). The common finding of all these studies is the signifi-
cant improvement in scores for lameness, as well as improvements in pain and 
range of motion (Black et al., 2007, 2008; Guercio et al., 2012). 
The results of our study concerning the initial evaluation period demon-
strated that AT-MSCs therapy led to a statistically significant large improvement 
for all five assessed disabilities characteristic of OA. The biggest change was de-
tected for lameness at trot, which is consistent with the majority of the published 
data. We would like to emphasise the results of the extended follow-up of this 
study, since, to the best of our knowledge, this is the longest follow-up of thera-
peutic outcomes related to the use of MSCs for the treatment of canine OA. A 
long-lasting positive effect was detected for two out of five analysed characteris-
tics. Namely, for lameness at trot and for the range of motion of the joints, a sta-
tistically significant large improvement was shown even 1 to 4 years after the ini-
tial evaluation period. Also, as for the initial evaluation period, the biggest 
change was observed for lameness at trot. It is important to point out that there 
were no adverse effects detected in any patient throughout the complete evalua-
tion period. 
Thus, the obtained results demonstrate a successful canine OA therapy us-
ing autologous AT-MSCs and represent a contribution to current scientific stud-
ies in this area. In addition, the data gained in this study may influence the direc-
tion of AT-MSCs applications in humans. Namely, dogs are recognised to be a 
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superior model to other commonly used species (such as rodents) based on dis-
ease mechanism, anatomical and clinical similarities to humans, and response to 
treatments (Chu et al., 2010; de Bakker et al., 2013). Consequently, the Osteoar-
thritis Research Society International (OARSI) recommended dogs as the appro-
priate model for studying the pathogenesis of OA and for the comparative and 
translational studies of OA (Cook et al., 2010). This is significant since two-
thirds of the aged human population are affected by different types of OA 
(Deschner et al., 2003; Verbruggen, 2006). 
Some of the limitations of this type of scientific studies are the relatively 
small sample size of patients, and even more, the recruitment of patients for 
blinded, controlled trials (Black et al., 2008; Cuervo et al., 2014). This set-up is 
difficult to achieve, especially in veterinary science, for logistic and economic 
reasons (de Bakker et al., 2013). An additional limitation lies in the fact that 
functional evaluation scales, which are routinely used in human medicine, are not 
established in veterinary medicine. Namely, in the literature related to the use of 
MSCs in the treatment of OA in dogs, various approaches of clinical evaluation 
are described. For example, regarding the evaluation of the range of motion of 
the joint there are studies in which this parameter was assessed using goniometer 
(Cuervo et al., 2014; Vilar et al., 2016), while in other studies, as well as in our 
study, it was assessed using pain as an indicator (Black et al., 2007, 2008; Guer-
cio et al., 2012). The latter approach has some limitations, since the pain in OA is 
a complex phenomenon composed of a number of different sensations from dif-
ferent sources (Salaffi et al., 2014). However, this approach is very informative, 
when it is coupled with pain on manipulation data obtained by evaluation meth-
odology as described in the Materials and methods section. In spite of these limi-
tations, the clinical use of MSCs in veterinary practice for commercial purposes 
has dramatically increased (Bernardo and Fibbe, 2013; Arnhold and Wenisch, 
2015). Unfortunately, the number of published results regarding the efficacy of 
MSCs treatment is not following that trend. If available, data from these treat-
ments, statistically validated to clinical or functional outcome measures, could 
help in the formulation of clear conclusions on the effectiveness of applied 
MSCs therapies (Jorgensen and Noel, 2012). Only by this approach would it be 
possible to correctly translate the potential therapeutic applications in veterinary 
and human medicine, thus providing a solid base for further research that will 
help in understanding the mechanisms by which MSCs promote tissue repair and 
regeneration. 
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